ALFA Finder| Revenue growth | FY26 revenue down 12% YoY; Q4 flat at ₹238cr. |
|---|---|
| Margins | Q4 margins stabilized as high-priced inventory was cleared. |
| Demand visibility | Stability appearing in non-regulated markets; US sterile demand high. |
| Management confidence | Shift from recovery to optimistic platform creation mode. |
Growth
FY26 revenue fell to ₹811cr from ₹922cr due to global pricing pressure, though Q4 showed stabilization with margins recovering to 17.7%.
Outlook
Targeting 10-15% growth in FY27; launching 5-6 large sterile products in the US, addressing a $1.2 billion market opportunity.
Risks
Continued global pricing volatility, high R&D/AMS platform drag (₹8cr annually), and heavy reliance on the US FDA facility approval timeline.
Earnings Call filed with NSE, NSE: ORCHPHARMA. Summary written with AI assistance from the document.
Orchid Pharma Ltd: key numbers
- Share price
- ₹884.40
- Market cap
- ₹5,296 Cr
- Revenue (annual)
- ₹811.3 Cr
- Net profit (annual)
- ₹20.55 Cr
- P/E (TTM)
- 611.0×Sector 43.7×
- Promoter holding
- 74.45%+4.61% QoQ
- FII holding
- 0.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Orchid Pharma Ltd
All →Orchid Pharma Other Announcement
Orchid Pharma's QIP monitoring report for the quarter ended September 2026 shows no deviation from objects. It flags revised fund allocation and delayed Jammu facility commercial operations.
Orchid Pharma Board Meeting Date
Orchid Pharma Ltd intimated that its board will meet on November 14, 2026 to consider Q2 and half-year unaudited results. The trading window stays closed until 48 hours after results declaration.
Orchid Pharma Partnership
Orchid Pharma entered a licensing and supply agreement with Laboratorio Libra for Exblifep across nine Latin American markets. The partnership is expected to represent a potential opportunity of about USD 80 million over 10 years.
Orchid Pharma Fund Raise of ₹600 Cr
Orchid Pharma's board approved an enabling resolution to raise funds of up to ₹600 Crore through equity or debt securities via various permissible modes.
- Value
- ₹600.0 Cr
Orchid Pharma Other Announcement
The company submitted its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended September 30, 2026.
Orchid Pharma Board Meeting Date
Orchid Pharma has scheduled a board meeting for October 20, 2026, to consider options for raising funds. The company will explore various suitable funding avenues.